Abstract | CONTEXT: OBJECTIVE: To assess the impact of CC on serum IGF-1 and T levels in male acromegalic patients not controlled by surgery, radiotherapy, and/or medical treatment. STUDY DESIGN: In this prospective, open-label, single-center trial, CC (50 mg/d) was added to previous medical treatment for 3 months. Hormonal assessment was performed before and during the intervention. PATIENTS: Sixteen male patients (median age, 52.8 y; range, 36-79 y) met the following criteria: IGF-1 above the upper limit of normal range for at least 1 year despite the use of available medical therapies, and T levels within or below the third inferior tertile of normality. RESULTS: Serum IGF-1 levels decreased by 41% (mean ± SD, 424 ± 108 to 250 ± 83 ng/mL; P < .0004), leading 44% (seven of 16) of the patients to achieve normal IGF-1 levels. Total serum T levels increased by 209% (282 ± 201 to 497 ± 310 ng/dL), reaching normal levels in 67% (four of six) of those patients considered hypogonadal. CONCLUSIONS: Addition of CC should be considered an option in male acromegaly patients not controlled by current available options, with a considerable cost-saving benefit. Furthermore, improvement of T levels can be obtained in those patients with concurrent central hypogonadism.
|
Authors | Felipe H Duarte, Raquel S Jallad, Marcello D Bronstein |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 100
Issue 5
Pg. 1863-9
(May 2015)
ISSN: 1945-7197 [Electronic] United States |
PMID | 25738590
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Selective Estrogen Receptor Modulators
- Clomiphene
- Testosterone
- Insulin-Like Growth Factor I
|
Topics |
- Acromegaly
(blood, drug therapy)
- Adult
- Aged
- Clomiphene
(therapeutic use)
- Humans
- Hypogonadism
(blood, drug therapy)
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Middle Aged
- Prospective Studies
- Retreatment
- Selective Estrogen Receptor Modulators
(therapeutic use)
- Testosterone
(blood)
- Treatment Outcome
|